

CURRICULUM VITAE

PETER-BRIAN ANDERSSON MB.ChB., B.Sc.Med(Hons), D.Phil.

EDUCATION

1981-1986 University of Cape Town, South Africa: MB.ChB (cum laude)
1987-1988 University of Cape Town, South Africa: BSc.Med.(Hons)(Med.Biochem)
1988-1991 University of Oxford, United Kingdom: D.Phil.

LICENSURE

California - 1993 to present (#A52853)
Oregon - 1998 to present (#20964 – inactive)
United Kingdom - 1988 to present (#3372254 - inactive)
South Africa - 1987 to present (#MP30729 - inactive)

CERTIFICATION

Board Certified in Clinical Neurophysiology, American Board of Psychiatry and Neurology, 2001
Board Certified in Clinical Neurophysiology, American Board of Electrodiagnostic Medicine, 2000
Board Certified in Neurology, American Board of Psychiatry and Neurology, 1998

CURRENT HOSPITAL PRIVILEGES

Providence-Cedars Sinai Tarzana Medical Center Oct 2000-Present

PRINCIPAL POSITIONS HELD

University of Cape Town

Oct 1983-Oct 1984: Vice President, Medical Students Council
Oct 1984-Oct 1985: Chairman, Medical Residence
Jan-Dec 1987: Intern in Medicine, Surgery and ObGyn (4 months each)
Jan-Oct 1988: Researcher, Medical Research Council Regulatory Neuropeptides Unit

University of Oxford

Oct 1988-Oct 1989: Tutor in Pathology, New College and St. Hilda's College
Oct 1989-Jun 1992: College Lecturer in Immunology, Christ Church
Jun 1991-Jun 1992: Yamanouchi Junior Research Fellow in Cell Biology, Wolfson College

University of California, San Francisco

Jul 1992-Jun 1993: Intern in Internal Medicine
Jul 1993-Jun 1995: Resident in Neurology
Jul 1995-Jun 1996: Chief Resident in Neurology
Jul 1996-Aug 1997: Clinical Instructor & Multiple Sclerosis Fellow

Oregon Health Sciences University

Jun 1998-Aug 1998: Senior Instructor & Neuromuscular Fellow

Stanford University & Forbes Norris MDA/ALS Center

Aug 1998-Jun 1999: Neuromuscular Fellow
Jul 1999-Nov 1999: Clinical Instructor

Kaiser Permanente Woodland Hills Medical Center

Nov 1999-Oct 2000: Staff Neurologist

Neurology Private Practice

San Fernando Valley Neurologic Medical Group, Inc. Oct 2000-Jun 2017
Clinical Assistant Professor in Neurology UCLA 2001-2007
Clinical Associate Professor in Neurology UCLA 2008-present
Founder and CEO, Neurology Consulting, Inc. Jul 2017-Present
Stroke Program Co-Director, Tarzana Hospital 2011-2015
Co-Investigator examining physician IDEAS Study 2016-2017
Co-investigator examining physician National Research Institute XanADu Trial 2017-2019
Co-Investigator National Research Institute Lilly LDMC Study 2019

Principal Investigator National Research Institute T3D-959 Study 2019-Present
Medical Director for California, Alliance Neurodiagnostics 2018-Present
Medical Director, California Neurodiagnostics 2018-Present
Contracted speaker for Eli Lilly, Inc. 2017, 2019-Present
Contracted speaker for Biohaven Pharmaceuticals 2021

AWARDS

17th place South African National Science Olympiad 1980
12th highest school-leaving examination results out of the 6155 candidates in State
Harry Allschwang Merit Scholarship, University of Cape Town 1981-1986
Class Gold Medallist (Top Student) in ObGyn final examinations, University of Cape Town 1986
MB.Ch.B. degree awarded cum laude, University of Cape Town 1986
Medical Research Council Post-Intern Scholar, University of Cape Town 1987
Harry Crossley Study Grant, University of Cape Town 1987
Rhodes Scholar 1988-1991
G.A. Paul Memorial Scholar, University College, University of Oxford 1991-1992
Yamanouchi Junior Research Fellow, Wolfson College, University of Oxford 1991-1992
UCSF School of Medicine Class of 1995 Resident Teaching Award
UCSF School of Medicine Class of 1996 Resident Teaching Award
UCSF Chief Resident in Neurology, 1995-1996
Marquis Who's Who in America Science and Engineering 1996-7
Elected to Alpha Omega Alpha Honor Society by UCSF School of Medicine Class of 1997
Fellow, American Board of Electrodiagnostic Medicine, 2000
Ad Hoc Reviewer *Muscle & Nerve*
UCLA School of Medicine Neurology Department Outstanding Medical Student Teaching Award, 2006
UCLA School of Medicine Outstanding Tutor Award yearly 2007-10, 2012, 2014, 2015
UCLA School of Medicine Neurology Department Teaching Award, 2011
Golden Hammer Resident Teaching Award, Department of Neurology UCLA 2008
Southern California Super Doctors 2010-2021 *Los Angeles Magazine*, *SuperDoctors.com*
Noticed Expert Network Distinguished Physician, 2017
The Leading Physicians of the World Directory, 2018

MEMBERSHIP OF PROFESSIONAL AND SCIENTIFIC SOCIETIES

American Academy of Neurology
American Association of Electrodiagnostic Medicine
American Medical Association

PRESENTATIONS

Invited speaker, British Society of Toxicological Pathologists Autumn meeting, Royal Society of Medicine, London, 8th November, 1991.
Invited discussant, "Neurological Consequences of Immune Dysregulation - Lessons from HIV and MS" National MS Society workshop, Sanibel Island, Florida, U.S.A., 18-21 January 1992
Invited speaker, "Macrophage and microglial responses in CNS inflammation". Neuromodulation in Pharmacology conference, Institut Pasteur, Paris, 5-7 February 1992.
Invited speaker, UCSF CNS Injury and Edema Research Centre and Neonatal Brain Disorders Centre, 2 November 1994.
UCSF Department of Neurology Grand Rounds "Neuroimmunomodulation with IVIG" October 16, 1996.
Invited Speaker, National Multiple Sclerosis Society Northern California Chapter Annual General Meeting, Sacramento, August 23, 1996, Seattle Chapter Annual General Meeting, Seattle, October 19, 1996 and Southern California Chapter Meeting, Los Angeles, November 17, 1996.
49th American Academy of Neurology meeting, "Primary progressive MS: clinical characteristics and progression of disability" (poster). Boston, April 12-19, 1997.
Invited speaker, "A phase IV study of interferon-1a (Avonex®) for relapsing remitting MS". National launch of interferon beta 1-a, Dublin, Ireland, 12th November 1997.
Platform presentation 51st American Academy of Neurology Meeting, "Differentiating electrophysiological

characteristics of Hereditary neuropathy with liability to pressure palsy" Toronto, April 18-25, 1999.
 Clinical case presenter, Neuromuscular evening seminar, 51st Annual American Academy of Neurology meeting, Toronto, April 23, 1999
 Invited speaker, "Update in Multiple Sclerosis Therapies", National Multiple Sclerosis Society, Universal Hilton Hotel, Los Angeles, June 2, 2001
 Invited speaker, "The Neurological Examination" Encino-Tarzana Medical Center Grand Rounds, April 2004
 Invited speaker, "Neuromuscular Junction Disease", Resident Lecture, UCLA Medical Center Nov 17, 2004
 Invited speaker, "Peripheral Neuropathy", Medical Student Lecture, UCLA Medical Center 2006-12
 Invited speaker, "Stroke update", Providence Tarzana Medical Center Community Lecture 2011-15
 Invited speaker, "The Problem of Dementia" Forum hosted at Calvary Community Church, Westlake Aug 16, 2014
 Invited speaker, "Complex Regional Pain Syndrome" AAA Adjustors Meeting, City of Industry Dec 11, 2019

PUBLICATIONS

1. King JA, Davidson J, Mehl AI, Wakefield IK, Andersson P-B and Millar RP (1989) Gonadal steroid modulation of signal transduction and luteinising hormone release in cultured chicken pituitary cells. *Endocrinology* 124, 1830-1840.
2. Hudson DA, Andersson P-B, Krige JE and Terblanche J (1990) Perihepatic packing in liver rupture during pregnancy. *Journal of Obstetrics and Gynaecology* 9, 298-299.
3. Andersson P-B, Perry VH and Gordon S (1991) The kinetics and morphological characteristics of the macrophage-microglial response to kainic acid-induced neuronal degeneration. *Neuroscience* 42, 201-214.
4. Andersson P-B, Perry V. H. and Gordon S. (1991) The CNS acute inflammatory response to excitotoxic neuronal cell death. *Immunology Letters* 30, 177-183.
5. Andersson P-B, Perry V.H. and Gordon S. (1992) The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues. *Neuroscience* 48, 169-186.
6. Perry V.H. and Andersson P-B. (1992) The inflammatory response in the CNS. *Neuropathology and Applied Neurobiology* 18, 454-459.
7. Andersson P-B, Perry V.H. and Gordon S. (1992) Intracerebral injection of proinflammatory cytokines or leukocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system. *Journal of Experimental Medicine* 176, 255-259.
8. Perry V.H., Andersson P-B and Gordon S. (1993) Macrophages and inflammation in the central nervous system. *Trends in the Neurosciences* 16, 268-273.
9. Reid D.M., Perry V.H., Andersson P-B and Gordon S. (1993) Mitosis and apoptosis of microglia in vivo induced by an anti-CR3 antibody which crosses the blood-brain barrier. *Neuroscience* 56, 529-233.
10. Andersson P-B and Goodkin D.E. (1996) Current Pharmacologic Treatment of Multiple Sclerosis Symptoms. *Western J. Medicine* 165:313-317.
11. Andersson P-B, Waubant E and Goodkin D.E. (1997) How should we proceed with disease- modifying treatments for multiple sclerosis? *Lancet*. 349:586-587.
12. Andersson P-B and Goodkin DE (1997) Outcomes assessment in multiple sclerosis. In *Bailliere's Clinical Neurology*. Vol 6 Multiple Sclerosis, Miller DH (ed). Bailliere Tindall, London. pp 409-428
13. Andersson P-B and Goodkin DE (1997) Glucocorticosteroid therapy for multiple sclerosis: a critical review. *Journal of the Neurological Sciences*.16:16-25 .

14. Andersson P-B, Waubant E, Gee L, Goodkin DE (1999) Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. *Archives of Neurology*. 56:1138-1142
15. Waubant E, Goodkin DE, Sloan R, Andersson P-B, (1999) A pilot study of MRI activity before and during interferon beta-1a therapy. *Neurology*. 53: 874-876
16. Waubant E, Gee L, Sloan R, Rooney W, Andersson P-B, Stewart T, Vermathen M, Stabler G, Miller K, Goodkin D (1999) Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. *Neurology* 53:1397-1401
17. Waubant E, Sloan R, Andersson P-B, Goodkin D.E. (1999) [Effect of weekly intramuscular interferon beta 1-a on MRI lesions in patients with relapsing multiple sclerosis]. *Rev Neurol (Paris)* 155 Sup 2 S20-23.
18. Andersson P-B, Rando T. (1999) Childhood Neuromuscular diseases. *Current Opinion in Pediatrics*. 11:497-503.
19. Katz JS, Wolfe GI, Andersson P-B, Saperstein DS, Elliot JL, Nations SP, Bryan WW, Barohn RJ (1999) Brachial amyotrophic diplegia: a slowly progressive motor neuron disorder. *Neurology* 53:1071-1076.
20. Suhy J, Rooney WD, Goodkin DE, Capizzano AA, Maudsley AA, Waubant E, Andersson P-B, Weiner MW (2000) ¹H-MRS of normal appearing white matter and lesions in primary progressive MS: comparison with relapsing remitting MS. *Multiple Sclerosis* 6:148-155
21. Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P-B, Stewart T, Nelson S, Fischbein N, Coyle PK, Frohman E, Jacobs L, Holcenberg J, Lee M, Mocci S. (2000) A phase I trial of solubilized DR2:MBP⁸⁴⁻¹⁰² (AG284) in multiple sclerosis. *Neurology*. 54:1414-20.
22. Tregoning SK, Ballard RC, Andersson P-B, Fehler HG, van der Spuy ZM (2000) Antibodies to Chlamydia trachomatis in patients presenting with ectopic pregnancy at Groote Schuur Hospital. *S Afr Med. J.* 90:727-730
23. Andersson P-B, Yuen E, Katz JS, Parko K, So, YT (2000) The differentiating electrophysiologic characteristics of hereditary neuropathy with liability to pressure palsy. *Neurology*. 54:40-44.
24. Lin P.T., Andersson P-B, Distad BJ, Barohn RJ, Cho SC, So YT, Katz JS (2005) Bilateral phrenic neuropathy causing painless bilateral diaphragmatic paralysis. *Neurology* 65:499-501

BOOKS AND MONOGRAPHS

1. Perry V.H., Andersson P-B, Coffey P.J. and Gordon S. (1992) Macrophage- microglial responses to excitotoxin-induced degeneration in the central nervous system. In *Mononuclear phagocytes: biology of monocytes and macrophages* (ed. R. van Furth). Kluwer Academic, Netherlands, pp 35-44.
2. Perry V.H., Brown M.C. & Andersson P-B. (1992) Macrophage responses to central and peripheral nerve injury. In *Advances in Neurology Vol 59* (ed F.J. Seil) Raven Press, Ltd, New York, pp 309-314.
3. Perry V.H., Brown M.C. & Andersson P-B (1993) Manipulating macrophages in nervous system repair. In *Neuronal Cell Death and Repair*. A.C. Cuello (ed). Elsevier Science Publishers, 193-199.
4. Goodkin D.E., Shulman M., Winkelhake J, Waubant E., Andersson, P-B, Stewart T., Nelson S, Fischbein N, Coyle P.K., Frohmann E, Jacobs L, Holcenberg J, Lee M & Mocci, S. (2001) A Phase I trial of solubilized DR2:MBP (84-102) (AG284 in multiple sclerosis. In *Multiple Sclerosis: Tissue Destruction and Repair*. Kappos L, Johnson K. Informa Health Care, 337-9.